Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.

Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...

Medigene continuously strengthens and expands its patent portfolio by developing new 3S TCRs, integrating advanced technologies, and extending its existing patents to new regions. The Company now owns ...